Haleon plc (NYSE:HLN) Shares Sold by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC cut its stake in shares of Haleon plc (NYSE:HLN) by 84.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,793 shares of the company’s stock after selling 41,663 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Haleon were worth $74,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in HLN. Fiduciary Alliance LLC purchased a new position in shares of Haleon during the 4th quarter worth approximately $112,000. PFW Advisors LLC purchased a new stake in Haleon during the 4th quarter worth $99,000. Marcum Wealth LLC grew its stake in shares of Haleon by 19.7% in the fourth quarter. Marcum Wealth LLC now owns 24,714 shares of the company’s stock valued at $236,000 after buying an additional 4,074 shares in the last quarter. SeaCrest Wealth Management LLC purchased a new stake in shares of Haleon during the fourth quarter valued at approximately $102,000. Finally, Kathmere Capital Management LLC grew its stake in shares of Haleon by 131.4% during the fourth quarter. Kathmere Capital Management LLC now owns 47,099 shares of the company’s stock valued at $449,000 after acquiring an additional 26,744 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Trading Up 1.7 %

Shares of HLN stock opened at $10.75 on Friday. The company has a market capitalization of $48.48 billion, a P/E ratio of 31.62, a P/E/G ratio of 2.82 and a beta of 0.24. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 12-month low of $8.24 and a 12-month high of $10.85. The firm has a 50-day moving average price of $10.20 and a 200 day moving average price of $9.84.

Haleon (NYSE:HLN) last released its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. Research analysts forecast that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The firm also recently announced a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be paid a dividend of $0.1166 per share. This represents a yield of 1.6%. This is a boost from Haleon’s previous — dividend of $0.05. The ex-dividend date is Friday, April 25th. Haleon’s dividend payout ratio is presently 58.97%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on HLN shares. HSBC reissued a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Barclays restated an “overweight” rating on shares of Haleon in a research report on Tuesday. Morgan Stanley upgraded shares of Haleon from an “equal weight” rating to an “overweight” rating and set a $11.25 target price for the company in a report on Friday. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Haleon in a report on Monday, March 3rd. Finally, Hsbc Global Res downgraded Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Five analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $11.25.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.